Poolbeg Pharma PLC Announces Director Share Purchase

LONDON, UK / ACCESSWIRE / February 19, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF)('Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has received notification that on 19 February 2024, Cathal Friel, Executive Chairman of the Company, purchased 830,000 ordinary shares at a price of 11.68 pence per share (the "Purchase").

Following the Purchase, Cathal holds 37,219,757 ordinary shares representing approximately 7.4 per cent of the Company's issued share capital.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 (as implemented into English law) ("MAR"). With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

Enquiries

Poolbeg Pharma Plc		[phone]
Jeremy Skillington, CEO
Ian O'Connell, CFO
Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)		[phone]
Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)
Singer Capital Markets (Joint Broker)		[phone]
Phil Davies, Sam Butcher
J&E Davy (Joint Broker)		[phone]
Anthony Farrell, Niall Gilchrist
Optimum Strategic Communications		[phone]
Nick Bastin, Vici Rabbetts, Elena Bates		[e-mail]

About Poolbeg Pharma